ATE400267T1 - Zusammensetzung zur potenzierung von krebs- chemotherapeutika - Google Patents

Zusammensetzung zur potenzierung von krebs- chemotherapeutika

Info

Publication number: ATE400267T1
Authority: AT; Austria
Prior art keywords: potentifying; composition; cancer chemotherapeutics; vitamin; cancer
Prior art date: 2000-09-01

Application number

AT01964398T

Other languages

English (en)

Inventor

Raxit Jariwalla

Original Assignee

Ester C Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-01

Filing date

2001-08-24

Publication date

2008-07-15

2001-08-24 Application filed by Ester C Company filed Critical Ester C Company

2008-07-15 Application granted granted Critical

2008-07-15 Publication of ATE400267T1 publication Critical patent/ATE400267T1/de

Links

206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-M L-ascorbate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CIWBSHSKHKDKBQ-JLAZNSOCSA-M 0.000 abstract 1
150000000994 L-ascorbates Chemical class 0.000 abstract 1
229930003268 Vitamin C Natural products 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002241 furanones Chemical class 0.000 abstract 1
229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
239000011707 mineral Substances 0.000 abstract 1
235000019154 vitamin C Nutrition 0.000 abstract 1
239000011718 vitamin C Substances 0.000 abstract 1
150000003700 vitamin C derivatives Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01964398T 2000-09-01 2001-08-24 Zusammensetzung zur potenzierung von krebs- chemotherapeutika ATE400267T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/654,377 US6468980B1 (en)	2000-09-01	2000-09-01	Methods and compositions for potentiating cancer chemotherapeutic agents

Publications (1)

Publication Number	Publication Date
ATE400267T1 true ATE400267T1 (de)	2008-07-15

Family

ID=24624611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01964398T ATE400267T1 (de)	2000-09-01	2001-08-24	Zusammensetzung zur potenzierung von krebs- chemotherapeutika

Country Status (15)

Country	Link
US (1)	US6468980B1 (de)
EP (1)	EP1286674B1 (de)
JP (1)	JP2004508335A (de)
KR (1)	KR20030019297A (de)
AT (1)	ATE400267T1 (de)
AU (1)	AU8525401A (de)
CA (1)	CA2389602A1 (de)
CY (1)	CY1108787T1 (de)
DE (1)	DE60134740D1 (de)
DK (1)	DK1286674T3 (de)
ES (1)	ES2309085T3 (de)
MX (1)	MXPA02004327A (de)
PT (1)	PT1286674E (de)
TR (1)	TR200201192T1 (de)
WO (1)	WO2002020023A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6878744B2 (en) *	1999-02-05	2005-04-12	Oxycal Laboratories, Inc.	Vitamin C compositions
CN1197561C (zh) *	2001-07-03	2005-04-20	北京巨能亚太生命科学研究中心	L－苏糖酸钙在制备预防或治疗损及软骨的疾病的药物中的用途
WO2005018633A1 (en)	2003-08-13	2005-03-03	Oxycal Laborataries, Inc.	Methods for the amelioration of environmental oxidant stress and the regulation of beneficial genes
CA2676841C (en) *	2007-01-31	2017-09-26	Rutgers, The State University Of New Jersey	Controlled release of actives in skin
KR101998246B1 (ko) *	2018-08-22	2019-07-10	주식회사 메타파인즈	금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
TR2022000209A2 (tr)	2022-01-07	2022-02-21	Oezge Gueven	Ozoni̇ze c-vi̇tami̇ni̇ i̇çeren bi̇r anti̇-kanser i̇laci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6846687A (en) *	1985-12-05	1987-06-30	American Biotechnology Co. Ltd.	Anthracycline type antitumor agents with l-ascorbic acid
GB8810173D0 (en) *	1988-04-29	1988-06-02	Norsk Hydro As	Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
WO1990012571A1 (en) *	1989-04-07	1990-11-01	Oxycal Laboratories, Inc.	Compositions and methods for administering vitamin c
JPH08291075A (ja) *	1995-04-20	1996-11-05	Showa Denko Kk	癌転移阻害剤
EP0875246A1 (de) *	1997-04-04	1998-11-04	Showa Denko Kabushiki Kaisha	Pharmazeutische Zusammensetzung aus Ascorbinsäurederivate zur Behandlung von Krebs
AU744584B2 (en) *	1998-02-06	2002-02-28	Ester C Company, The	Stable liquid mineral ascorbate compositions and methods of manufacture and use
JP2003508437A (ja) *	1999-08-30	2003-03-04	オキシカル・ラボラトリーズ・インク	選択的癌化学療法及び該療法用の組成物

2000
- 2000-09-01 US US09/654,377 patent/US6468980B1/en not_active Expired - Lifetime
2001
- 2001-08-24 KR KR1020027005605A patent/KR20030019297A/ko not_active Ceased
- 2001-08-24 DE DE60134740T patent/DE60134740D1/de not_active Expired - Lifetime
- 2001-08-24 JP JP2002524507A patent/JP2004508335A/ja active Pending
- 2001-08-24 AT AT01964398T patent/ATE400267T1/de not_active IP Right Cessation
- 2001-08-24 ES ES01964398T patent/ES2309085T3/es not_active Expired - Lifetime
- 2001-08-24 CA CA002389602A patent/CA2389602A1/en not_active Abandoned
- 2001-08-24 TR TR2002/01192T patent/TR200201192T1/xx unknown
- 2001-08-24 WO PCT/US2001/026455 patent/WO2002020023A1/en not_active Ceased
- 2001-08-24 DK DK01964398T patent/DK1286674T3/da active
- 2001-08-24 MX MXPA02004327A patent/MXPA02004327A/es active IP Right Grant
- 2001-08-24 PT PT01964398T patent/PT1286674E/pt unknown
- 2001-08-24 AU AU85254/01A patent/AU8525401A/en not_active Abandoned
- 2001-08-24 EP EP01964398A patent/EP1286674B1/de not_active Expired - Lifetime
2008
- 2008-09-23 CY CY20081101028T patent/CY1108787T1/el unknown

Also Published As

Publication number	Publication date
WO2002020023A1 (en)	2002-03-14
AU8525401A (en)	2002-03-22
DK1286674T3 (da)	2008-11-03
EP1286674B1 (de)	2008-07-09
EP1286674A4 (de)	2005-12-21
PT1286674E (pt)	2008-08-21
CA2389602A1 (en)	2002-03-14
US6468980B1 (en)	2002-10-22
TR200201192T1 (tr)	2003-05-21
EP1286674A1 (de)	2003-03-05
MXPA02004327A (es)	2002-11-07
KR20030019297A (ko)	2003-03-06
DE60134740D1 (de)	2008-08-21
CY1108787T1 (el)	2014-04-09
ES2309085T3 (es)	2008-12-16
JP2004508335A (ja)	2004-03-18

Legal Events

Date

Code

Title

Description

2008-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1286674

Country of ref document: EP

2011-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
BR0113798A (pt)	2003-07-08	Derivados de resorcinol
TR200000782T2 (tr)	2000-09-21	Resorsinol türevleri.
ES2153337T1 (es)	2001-03-01	Inhibidores de raf-quinasa.
MXPA03007140A (es)	2004-05-24	Derivados de carbolina.
ES2184149T3 (es)	2003-04-01	Paclitaxeles 6-tio sustituidos.
MXPA04004347A (es)	2004-08-11	Nuevos fotoindicadores difuncionales.
MXPA03010134A (es)	2004-03-10	Derivados de ciclohexan-1-4-diamina sustituidos.
DE602004012083D1 (de)	2008-04-10	Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
BR0209149A (pt)	2004-07-13	Ftalazinonas
ATE496109T1 (de)	2011-02-15	Umsetzungsprodukte von mercaptobenzothiazolen, mercaptothiazolinen und mercaptobenzimidazolen mit epoxiden als schmiermitteladditive
CY1108787T1 (el)	2014-04-09	Συνθεση για ενισχυση χημειοθεραπευτικων παραγοντων καρκινου
TR200102742T2 (tr)	2002-05-21	Rezorsinol türevleri
ATE288922T1 (de)	2005-02-15	Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
SE9903290D0 (sv)	1999-09-15	Novel compounds
TR200402030T4 (tr)	2004-09-21	İkame edilen I-aminobutan-3-ol-türevleri
DE60026350D1 (de)	2006-04-27	Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel
BR0208221A (pt)	2004-03-02	Combinação de uma taxano e uma cinase dependente de ciclina
TR200302193T4 (tr)	2004-02-23	Kombinasyon kemoterapisi.
ATE298328T1 (de)	2005-07-15	Taxan-derivate für die behandlung von krebs
DE60134814D1 (de)	2008-08-28	C10-carbamoyloxysubstituierte taxane als antitumormittel
DE60136706D1 (de)	2009-01-08	Ycin-acryloyl derivate und antimetabolische mitteln
DE60133600D1 (de)	2008-05-29	C7-carbamoyloxysubstituierte taxane als antitumormittel
DK1521752T3 (da)	2009-06-22	Makrocykliske forbindelser til behandling af cancer
BR0113202A (pt)	2003-07-01	Compostos de trioxepano
BR0214244A (pt)	2004-09-21	Uso de uma ascomicina